Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Products under Development by Stage of Development | 7 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Products under Development by Therapy Area | 8 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Products under Development by Indication | 9 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Products under Development by Companies | 12 | 2 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Products under Development by Universities/Institutes | 14 | 2 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Companies Involved in Therapeutics Development | 21 | 3 |
| eFFECTOR Therapeutics, Inc. | 21 | 1 |
| Ionis Pharmaceuticals, Inc. | 22 | 1 |
| Onconova Therapeutics, Inc. | 23 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Drug Profiles | 24 | 7 |
| 4EGI-1 Drug Profile | 24 | 1 |
| briciclib sodium Drug Profile | 25 | 1 |
| ISIS-EIF4ERx Drug Profile | 26 | 2 |
| SBI-756 Drug Profile | 28 | 1 |
| Small Molecule to Inhibit eIF4E for Oncology Drug Profile | 29 | 1 |
| Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology Drug Profile | 30 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Dormant Projects | 31 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Discontinued Products | 32 | 1 |
| Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Featured News &Press Releases | 33 | 4 |
| Nov 24, 2015: Scientists identify promising new melanoma drug | 33 | 1 |
| Oct 29, 2015: Onconova Therapeutics to Present New Data on Briciclib at 2015 AACR-NCI-EORTC Meeting | 34 | 1 |
| Apr 21, 2015: Onconova Therapeutics Highlights Briciclib at the 2015 American Association of Cancer Research (AACR) Annual Meeting | 34 | 1 |
| Jan 04, 2011: Isis Initiates Phase II Lung Cancer Trial With ISIS-EIF4ERx In Combination With Carboplatin And Paclitaxel | 35 | 1 |
| Feb 01, 2006: Lilly Initiates Clinical Trials On Second Cancer Drug Discovered In Isis Collaboration | 36 | 1 |
| Jun 24, 2002: Expansion Of Antisense Agreement Between Isis And Eli Lilly | 36 | 1 |
| Appendix | 37 | 2 |
| Methodology | 37 | 1 |
| Coverage | 37 | 1 |
| Secondary Research | 37 | 1 |
| Primary Research | 37 | 1 |
| Expert Panel Validation | 37 | 1 |
| Contact Us | 37 | 1 |
| Disclaimer | 38 | 1 |